Gilead Sciences has announced that on July 28, it will release its second quarter 2015 financial results. On that day at 4.30 pm Eastern Time, it will have to host a conference call to discuss the results and will update on general business.

People who are interested in the discussion can access the same at the company's investigator page. It has been suggested that people should connect with the company's website 15 minutes before the start of the call.

If a market look is taken then Gilead Sciences Inc. valued at $173.09B started trading at $118.18 this morning. It traded between $116.92 and $118.98. Over the past 12 months, it has traded between $85.30 and $123.37.

As per the 19 analysts, the earnings estimation is $2.70 per share, which would prove $0.34 better than a year-ago quarter. According to them, complete year EPS estimation is $10.83, which is again better than last year.

Analysts' average price target for GILD shares is $123.89. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes medicines in areas where not many treatments are available.

The company aims to improve the care of patients who suffer from life-threatening disease. The company operates in over 30 nations across the globe and is headquartered in Foster City, California.